Rockwell Medical Says Phase 3 CRUISE Trial Data Accepted As LBCT Abstract

(RTTNews) - Rockwell Medical, Inc. (RMTI), a biopharmaceutical company targeting end stage renal disease and chronic kidney disease with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported that the Phase 3 CRUISE-1 and CRUISE-2 clinical abstract submitted as a Late-Breaking Clinical Trial or LBCT to the ASN LBCT subcommittee has been accepted for poster presentation at the ASN Kidney Week 2013 Annual Meeting, November 7-10 in Atlanta, GA.

The abstract would be presented under the Late-Breaking Posters as "Continuous, Maintenance Iron Therapy Using Soluble Ferric Pyrophosphate Citrate Chelate Infusion via Hemodialysate in CKD-HD: Phase III CRUISE Studies". The firm would provide further information, including date, time and presenter prior to the ASN annual meeting taking place November 7-10 in Atlanta, GA.